Treatment of Chlamydophila pneumoniae pneumonia in adult inpatients with nonsevere community-acquired pneumonia
This protocol covers empiric antibiotic management for adults hospitalised with nonsevere community-acquired pneumonia (CAP) in which Chlamydophila pneumoniae is a causative or suspected pathogen, in patients who do not carry additional resistance risk.
Clinical scenario
Adult inpatient with nonsevere community-acquired pneumonia, without risk factors for MRSA or Pseudomonas aeruginosa — specifically, no prior respiratory isolation of either organism and no recent hospitalisation with receipt of parenteral antibiotics in the preceding 90 days.
Antibiotic approach
The protocol specifies empiric regimens for this population — involving either combination antibiotic therapy or a monotherapy option. Selection among these approaches, along with the full agents and duration criteria, is detailed in the structured protocol.
Treatment goal
The target is clinical stability: resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation. Most patients are expected to reach stability within 48 to 72 hours, with therapy continued for a minimum of 5 days.
References
In inpatient adults with nonsevere CAP without risk factors for MRSA or P. aeruginosa (see Recommendation 11), we recommend the following empiric treatment regimens (in no order of preference) (Table 4):
combination therapy with a b-lactam (ampicillin + sulbactam 1.5-3 g every 6 h, cefotaxime 1-2 g every 8 h, ceftriaxone 1-2 g daily, or ceftaroline 600 mg every 12 h) and a macrolide (azithromycin 500 mg daily or clarithromycin 500 mg twice daily) (strong recommendation, high quality of evidence), or monotherapy with a respiratory fluoroquinolone (levofloxacin 750 mg daily, moxifloxacin 400 mg daily) (strong recommendation, high quality of evidence). A third option for adults with CAP who have contraindications to both macrolides and fluoroquinolones is: combination therapy with a b-lactam (ampicillin + sulbactam, cefotaxime, ceftaroline, or ceftriaxone, doses as above) and doxycycline 100 mg twice daily (conditional recommendation, low quality of evidence).
We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence). As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients.
DOI: 10.1164/rccm.201908-1581ST
View source ↗